Santen Wins South Korean Approval for Ryjusea Myopia Treatment

Bitget2026/11/02 06:36

By:Bitget

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Santen Pharmaceutical secured South Korean marketing approval for STN1012700 (Ryjusea 0.25mg/mL Ophthalmic Solution) to slow myopia progression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Santen Pharmaceutical Co. Ltd. published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Santen Wins South Korean Approval for Ryjusea Myopia Treatment

You may also like

Crypto prices